Well being and Human Companies Secretary Robert F. Kennedy couldn’t cough up solutions when pressed concerning the Trump administration’s actions that might enhance drug costs for seniors, leaving one senator baffled.
Whereas testifying earlier than the Senate Finance Committee Thursday, Kennedy was requested by Senator Catherine Cortez Masto on his help of the carve-outs for high-cost most cancers medicine from Medicare value discount negotiations in Trump’s behemoth price range invoice.
“So my query to you, Mr. Secretary, is how do you justify claiming to tackle Huge Pharma whereas supporting a invoice that shields medicine, like Keytruda and different most cancers medicine, from Medicare negotiation, costing seniors and taxpayers billions, and risking the lives of most cancers sufferers who can not afford the mandatory medicine?”
Kennedy replied that the deliberate value discount negotiations specified by the 2022 Inflation Discount Act have been “very well-intentioned, however they have been poorly structured,” and added that earlier negotiations had raised Medicare costs.
Cortez Masto interjected that Kennedy’s claims didn’t match the findings of the Congressional Price range Workplace. Trump and different Republicans have spent months making an attempt to discredit the CBO’s findings as they warn of the consequences of the president’s calamitous price range invoice. “The CBO doesn’t say that, it’s simply the alternative. So that you’re saying that the CBO and impartial companies that validate the prices are unsuitable?”
Kennedy claimed that the information was from the Facilities for Medicaid and Medicare Companies (CMS).
The Nevada Democrat didn’t relent, and when pressed on why these medicine had been exempt by Trump’s laws, Kennedy stated he was “undecided” of that provision.
“Your company is answerable for that negotiation, and also you don’t learn about it?” Cortez Masto requested incredulously.
Cortez Masto tried to get particular, asking Kennedy if he knew how a lot individuals enrolled in Medicare Half D and Half B have been anticipated to pay for prescription drug prices subsequent 12 months.
Every query elicited a protracted pause from Kennedy. He stammered solutions that included “I believe that that’s in debate proper now—” and even, “I don’t know.”
Cortez Masto defined that costs have been anticipated to extend for Half D enrollees by $15, as much as $50 a month. Half B enrollees may count on value will increase of 11.6 %, or $21.50 extra every month. Medicare premiums have been anticipated to have the most important single 12 months value enhance in many years as a result of the Trump administration had lower the federal subsidy that has been maintaining prices down, she stated.
Cortez Masto then tried to simplify her query even additional. “My query to you is, what are you doing to maintain prices down for seniors?” Cortez Masto pressed. Kennedy wilted.
“I imply, I’m already doing—I’m already maintaining prices down,” he stated.
“What are you doing to maintain prices down for seniors, understanding that these prices are going to be rising?” she requested once more.
Kennedy touted a Program Integrity Invoice, which CMS stated may decrease premiums by 5 % (the CBO contends it’s nearer to 0.6 %.) “And does that influence seniors?” Cortez Masto pressed once more.
“Excuse me?” Kennedy stated.
“Does that influence seniors?” she stated.“Does that influence seniors? What you simply talked about, you’re decreasing prices, does that influence seniors?
“Does it influence…?” Kennedy stated, showing confused despite the fact that he’d heard the identical query repeated a number of instances. “I didn’t hear your query,” he pouted.
Whereas the senators’ microphones lower out at completely different moments throughout Kennedy’s listening to Thursday, that hadn’t been the case throughout Cortez Masto’s questioning. It appears clear that Kennedy heard—he simply didn’t have something sensible to say.
